Mercia announced Tozaro’s £6m round to reduce the cost of breakthrough gene therapies.
Tozaro Limited is developing a novel suite of reagents to help transform the development and manufacture of viral vectors in cell and gene therapy
Tozaro Limited is developing a novel suite of reagents to help transform the development and manufacture of viral vectors in cell and gene therapy. The company leverages molecular modeling, machine learning, and chemical synthesis to design and build custom affinity ligands tailored to viral vectors and applications.